Analyst Ratings For NASDAQ:AKCA – Akcea Therapeutics (NASDAQ:AKCA)
Today, NASDAQ:AKCA – Akcea Therapeutics (NASDAQ:AKCA) stock received an upgrade by Wells Fargo from Market Perform ➝ Outperform.
Some recent analyst ratings include
- 5/11/2018-Wells Fargo Upgrade from a “Market Perform ➝ Outperform” rating to a “” rating.
- 2/27/2018-Cowen was Downgraded by analysts at Cowen from a “Outperform ➝ Market Perform” rating to a “” rating.
Recent Insider Trading Activity For NASDAQ:AKCA – Akcea Therapeutics (NASDAQ:AKCA)
NASDAQ:AKCA – Akcea Therapeutics (NASDAQ:AKCA) has insider ownership of 3.88% and institutional ownership of 29.06%.
- On 4/17/2018 Ionis Pharmaceuticals Inc, Major Shareholder, bought 10,666,666 with an average share price of $18.75 per share and the total transaction amounting to $199,999,987.50.
- On 7/19/2017 Ionis Pharmaceuticals Inc, Major Shareholder, bought 3,125,000 with an average share price of $8.00 per share and the total transaction amounting to $25,000,000.00.
Recent Trading Activity for NASDAQ:AKCA – Akcea Therapeutics (NASDAQ:AKCA)
Shares of NASDAQ:AKCA – Akcea Therapeutics closed the previous trading session at with 388509 shares trading hands.
